136 related articles for article (PubMed ID: 11054987)
1. Clinical pharmacology of encapsulated sustained-release cytarabine.
Murry DJ; Blaney SM
Ann Pharmacother; 2000 Oct; 34(10):1173-8. PubMed ID: 11054987
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Phuphanich S; Maria B; Braeckman R; Chamberlain M
J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
Angst MS; Drover DR
Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
Glantz MJ; LaFollette S; Jaeckle KA; Shapiro W; Swinnen L; Rozental JR; Phuphanich S; Rogers LR; Gutheil JC; Batchelor T; Lyter D; Chamberlain M; Maria BL; Schiffer C; Bashir R; Thomas D; Cowens W; Howell SB
J Clin Oncol; 1999 Oct; 17(10):3110-6. PubMed ID: 10506606
[TBL] [Abstract][Full Text] [Related]
6. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
Jaeckle KA; Batchelor T; O'Day SJ; Phuphanich S; New P; Lesser G; Cohn A; Gilbert M; Aiken R; Heros D; Rogers L; Wong E; Fulton D; Gutheil JC; Baidas S; Kennedy JM; Mason W; Moots P; Russell C; Swinnen LJ; Howell SB
J Neurooncol; 2002 May; 57(3):231-9. PubMed ID: 12125986
[TBL] [Abstract][Full Text] [Related]
7. Current treatment approaches for neoplastic meningitis: nursing management of patients receiving intrathecal DepoCyt.
Craig C
Oncol Nurs Forum; 2000 Sep; 27(8):1225-30; quiz 1231-2. PubMed ID: 11013903
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis.
Cole BF; Glantz MJ; Jaeckle KA; Chamberlain MC; Mackowiak JI
Cancer; 2003 Jun; 97(12):3053-60. PubMed ID: 12784341
[TBL] [Abstract][Full Text] [Related]
9. Response to intrathecal infusions of Depocyt® in secondary diffuse leptomeningeal gliomatosis. A case report.
Beauchesne P; Blonski M; Brissart H
In Vivo; 2011; 25(6):991-3. PubMed ID: 22021694
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.
Jaeckle KA; Phuphanich S; Bent MJ; Aiken R; Batchelor T; Campbell T; Fulton D; Gilbert M; Heros D; Rogers L; O'Day SJ; Akerley W; Allen J; Baidas S; Gertler SZ; Greenberg HS; LaFollette S; Lesser G; Mason W; Recht L; Wong E; Chamberlain MC; Cohn A; Glantz MJ; Gutheil JC; Maria B; Moots P; New P; Russell C; Shapiro W; Swinnen L; Howell SB
Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of cytarabine formulations.
Hamada A; Kawaguchi T; Nakano M
Clin Pharmacokinet; 2002; 41(10):705-18. PubMed ID: 12162758
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Chamberlain MC
J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology.
Howell SB
Cancer J; 2001; 7(3):219-27. PubMed ID: 11419030
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
Vazquez Fuster IB; Taylor AR; Smith AN; Duran SH; Ravis WR; Jasper SL; Arnold RD
J Vet Intern Med; 2020 Jul; 34(4):1563-1569. PubMed ID: 32442344
[TBL] [Abstract][Full Text] [Related]
16. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
17. [Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan].
Nakagawa H; Tamura M; Fukushima Y; Majima S; Yamada K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1799-805. PubMed ID: 18030013
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis.
Jahn F; Jordan K; Behlendorf T; Globig C; Schmoll HJ; Müller-Tidow C; Jordan B
Oncology; 2015; 89(3):137-42. PubMed ID: 25791073
[TBL] [Abstract][Full Text] [Related]
19. [Intrathecal chemotherapy treatment of neoplastic meningitis from solid tumors using liposomal cytarabine: experience at the Istituto Regina Elena di Roma].
Pace A
Tumori; 2007; 93(3):suppl 9-12. PubMed ID: 17679481
[No Abstract] [Full Text] [Related]
20. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
